Monument Therapeutics leads the charge in revolutionizing central nervous system disease treatment. Employing precision medicine, Monument integrates validated digital biomarkers and innovative CNS-active compounds to address unmet needs in psychiatry and neurology. Their innovative approach identifies homogeneous patient subtypes, enabling targeted treatments for serious central nervous system diseases.

Status | Active |
Website | https://monumenttx.com/ |
Category | Biotech |
Modality | Small Molecule |
Therapautics Area | Neurosciences |
Headquaters | Cambridge, UK |
Investment Portfolio | Fund Investment |
Co-Investors | Catapult Ventures, Cambridge Angels and Meltwind |